FeesSafety
Pluang+

Acoramidis cuts heart failure risk by 23-45% vs tafamidis in real-world and clinical studies for ATTR-CM

Market News
17 Nov 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
Acoramidis cuts heart failure risk by 23-45% vs tafamidis in real-world and clinical studies for ATTR-CM

Acoramidis, an oral transthyretin stabilizer, significantly reduces heart failure events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Real-world German data showed a 23% lower risk of worsening heart failure compared to tafamidis, while clinical trials demonstrated a 45% reduction in first heart failure events versus placebo, with benefits appearing within one month. The drug also lowered heart failure hospitalizations, mortality, and outpatient worsening events, with sustained benefits through 54 months. These findings reinforce acoramidis as a fast-acting, effective treatment option for ATTR-CM, with additional kidney-protective effects and broad applicability across patient subgroups.

Acoramidis, noted for reducing heart failure events by 45% in clinical trials, is presented here alongside Pluang's health sector market snapshot. As of Nov 17, 2026 18:51 WIB, out of 150 priced US health stocks, 51 rose and 91 fell. Notable movers include SYRE at USD 86.93 with a 12.52% decline, SLS at USD 8.00 gaining 7.10% with 96% buy orders, and SANA at USD 2.00 up 6.38% with 100% buy orders, reflecting diverse market activity.

More News

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene Inc. and City of Hope have started a Phase 1 clinical trial testing a new combination therapy for metastatic colorectal cancer patients resistant to standard treatments. The trial evaluates two experimental drugs, ivonescimab and muzastotug (...

Others
Bullish
58 minutes ago
Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank announced three key leadership appointments to strengthen its Commercial Banking division. Edward Galan will lead Middle Market Lending, Dawn Scocco will manage portfolio and credit risk, and John Maio will head Treasury Management Ser...

Market News
Bullish
58 minutes ago
RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand Company Ltd. has released its first mobile game, Palazzo Chronicles: Match 3, on the Google Play Store. The free-to-play match-3 puzzle game features over 270 levels where players restore a royal palace set in Risorgimento Italy. This launch...

Others
Bullish
58 minutes ago
Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan, with over 25 years in financial technology including roles at Goldman Sachs and Coinbase, has joined Dune as Director of Engineering. He will lead the engineering efforts behind Dune Market Data Feeds, which provide real-time trade and liq...

Others
Bullish
58 minutes ago
BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock, Inc. has increased its total voting rights in ICG PLC to 5.16% as of November 13, 2026, up from 5.17% previously reported. This includes 5.08% voting rights attached to shares and 0.08% through financial instruments. The notification was o...

Market News
Neutral
58 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App